The Massachusetts attorney general is looking into whether Gilead Sciences violated state consumer protection laws in its drug pricing. One of the drugs in question, Solvadi, costs $84,000 for a 12-week course of treatment. The median income for a United States household in 2014 was around $53,000.
Also last week, the nonprofit AIDS Healthcare Foundation, filed a lawsuit to invalidate Gilead's patient on an HIV drug, tenofovir.
The New York Times discusses both stories.
0 thoughts on “Massachusetts investigates drug overpricing for Hep C drugs”
I believe you mean “patent” in that middle paragraph, not “patient”.